

STATUS OF THE CLAIMS:

Kindly cancel claims 1-23, 25-27, 31-37, 39, 41-43 and 47-69 without prejudice.

The status of the claims is as follows:

Claims 1-23 (canceled)

24. (currently amended) A method of decreasing phagocytosis or ICAM-1 expression in a mammalian cell in need thereof, comprising contacting the cell with an a therapeutically phagocytosis- or ICAM-1 decreasing effective amount of an agent selected from the group consisting of soybean paste containing STI, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI that specifically increases phagocytosis or ICAM-1 expression.

Claims 25-27 (canceled)

28. (original) The method of claim 24, wherein the agent inhibits the PAR-2 pathway.

29. (currently amended) The method of claim 24, wherein the agent is selected from the group consisting of a soybean derivative paste containing STI and a serine protease inhibitor.

30. (currently amended) The method of claim 29, wherein the agent is selected from the group consisting of soybean paste containing STI, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.

Claims 31-37 (canceled)

38. (currently amended) A method of treating a mammal afflicted with a disorder ameliorated by a decrease in phagocytosis or ICAM-1 expression in appropriate cells, which comprises administering to the mammal a therapeutically effective amount of an agent that specifically decreases phagocytosis or ICAM-1 expression, said agent selected from the group

consisting of soybean paste containing STI, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.

Claim 39 (canceled)

40. (currently amended) A method of preventing in a mammal a disorder ameliorated by a decrease in phagocytosis or ICAM-1 expression in appropriate cells, which comprises administering to the mammal a therapeutically effective amount of an agent that specifically decreases phagocytosis or ICAM-1 expression, said agent selected from the group consisting of soybean paste containing STI, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.

Claims 41-43 (canceled)

44. (previously amended) The method of claim 38, wherein the agent inhibits the PAR-2 pathway.

45. (previously amended) The method of claim 38, wherein the agent is selected from the group consisting of a soybean derivative paste containing STI and a serine protease inhibitor.

46. (currently amended) The method of claim 45, wherein the agent is selected from the group consisting of ~~soybean milk~~, soybean paste containing STI, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.

Claims 47-69 (canceled)